Article
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.
Blood advances - 24 Feb 2026
Wei Andrew H, Panayiotidis Panayiotis, Montesinos Pau, Laribi Kamel, Ivanov Vladimir, Kim Inho, Novak Jan, Champion Rebecca, Fiedler Walter, Pagoni Maria, Bergeron Julie, Ting Stephen B, Hou Jing-Zhou, Yamauchi Takahiro, Wang Jianxiang, Strickland Stephen A, Savona Michael R, Lin Tara L, Enjeti Anoop, Tiong Ing Soo, Lee Sangmin, Roboz Gail J, Popovic Relja, Jiang Qi, Liu Zihuan, Sun Yan, Mendes Wellington, Chyla Brenda, DiNardo Courtney D
Abstract excerpt
ABSTRACT: Prognostic risk categorization aids treatment selection for patients with acute myeloid leukemia (AML). Although the European LeukemiaNet (ELN) classifications (2017 and 2022) for AML have been used to stratify outcomes for patients receiving intensive chemotherapy, their application to patients receiving less intensive therapy, such as azacitidine plus venetoclax, has been less satisfactory. In...
Topics
Join the communities discussing this publication.